Enveric Biosciences Q3 net loss $3.4M, cash $3.8M; EB-003 advances toward IND 2026

Enveric Biosciences, Inc.

2025-Q3 EPS reported -$35.74

Net loss of $3.4M ($10.81 per share) in Q3 2025 vs $2.1M ($43.10) in Q3 2024; cash $3.8M as of Sept 30, 2025.
Lead candidate EB-003: completed pre-IND dose range studies, positive PTSD data, FDA pre-IND response; IND planned 2026.
Hired Fish & Richardson to defend U.S. Patent 12,138,276 against Gilgamesh PGR; patent covers Bretisilocin (AbbVie, $1.2B).
Completed reverse stock split 1:12 on Oct 28, 2025 after Nasdaq bid price deficiency delisting determination.
Gross proceeds of ~$2.2M from warrant exercise; $7.9M net raised in first nine months of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.